14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $5.34 $19.02 Monday, 6th May 2024 STOK stock ended at $11.87. This is 1.25% less than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 5.67% from a day low at $11.65 to a day high of $12.31.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Stoke Therapeutics, Inc. prices

Date Open High Low Close Volume
May 06, 2024 $12.02 $12.31 $11.65 $11.87 608 896
May 03, 2024 $12.00 $12.60 $11.59 $12.02 524 301
May 02, 2024 $11.66 $11.98 $11.45 $11.69 506 951
May 01, 2024 $11.14 $11.82 $10.97 $11.56 788 942
Apr 30, 2024 $11.69 $11.93 $10.98 $11.03 756 881
Apr 29, 2024 $11.80 $12.72 $11.51 $11.86 908 877
Apr 26, 2024 $11.60 $12.43 $11.49 $12.41 891 942
Apr 25, 2024 $11.41 $11.82 $11.11 $11.69 507 869
Apr 24, 2024 $11.18 $12.04 $11.07 $11.66 1 474 441
Apr 23, 2024 $11.24 $11.87 $11.07 $11.25 601 239
Apr 22, 2024 $12.00 $12.00 $10.90 $11.25 1 288 158
Apr 19, 2024 $11.55 $12.20 $11.50 $12.05 1 008 987
Apr 18, 2024 $11.76 $12.27 $11.54 $11.65 1 052 070
Apr 17, 2024 $12.51 $12.97 $11.63 $11.72 739 960
Apr 16, 2024 $12.00 $12.76 $11.82 $12.45 390 323
Apr 15, 2024 $12.81 $12.82 $12.00 $12.21 364 937
Apr 12, 2024 $13.35 $13.82 $12.55 $12.77 524 396
Apr 11, 2024 $12.88 $13.61 $12.43 $13.50 522 225
Apr 10, 2024 $12.20 $13.01 $12.20 $12.76 600 888
Apr 09, 2024 $13.00 $13.30 $12.21 $12.85 1 770 068
Apr 08, 2024 $12.70 $13.49 $12.52 $13.00 991 020
Apr 05, 2024 $12.18 $12.86 $11.87 $12.57 633 876
Apr 04, 2024 $13.05 $13.89 $11.77 $12.17 887 301
Apr 03, 2024 $13.04 $13.49 $12.33 $12.82 1 328 962
Apr 02, 2024 $13.10 $13.11 $12.00 $13.08 1 998 492
Click to get the best stock tips daily for free!

About Stoke Therapeutics, Inc.

Stoke Therapeutics. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome,... STOK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT